首页> 外文期刊>Clinical therapeutics >Bioavailability of Two Single-Dose Oral Formulations of Omeprazole 20 mg: An Open-Label, Randomized Sequence, Two-Period Crossover Comparison in Healthy Mexican Adult Volunteers.
【24h】

Bioavailability of Two Single-Dose Oral Formulations of Omeprazole 20 mg: An Open-Label, Randomized Sequence, Two-Period Crossover Comparison in Healthy Mexican Adult Volunteers.

机译:奥美拉唑20 mg的两种单剂量口服制剂的生物利用度:健康墨西哥成人志愿者中的开放标签,随机序列,两期交叉比较。

获取原文
获取原文并翻译 | 示例
       

摘要

Background: Omeprazole is a proton-pump inhibitor that acts to reduce acid secretion in the stomach and is used for treating various acid-related gastrointestinal disorders. There are several generic formulations of omeprazole available in Mexico; however, a literature search failed to identify published data concerning the bioavailability of these formulations in the Mexican population. Objective: The aim of this study was to compare the bioavailability of 2 oral formulations of omeprazole 20-mg capsules, marketed for use in Mexico, in healthy volunteers: Inhibitron((R)) (test formulation) and LosecA((R)) 20 mg (reference formulation). Methods: This study used a single-dose, open-label, randomized sequence, 2 x 2 crossover (2 administration periods x 2 treatments) design to compare the 2 formulations. Eligible subjects were healthy adult Mexican volunteers of both sexes. Subjects were randomly assigned in a 1:1 ratio to receive a single 20-mg dose of the test formulation followed by the reference formulation, or vice versa, with a 7-day washout period between administration periods. After a 12-hour (overnight) fast, subjects received a single, 20-mg dose of the corresponding formulation. Plasma samples were obtained over a 12-hour period after administration. Plasma omeprazole concentrations were analyzed by a nonstereospecific high-performance liquid chromatography method. For analysis of pharmacokinetic properties, including C(max), AUC from time 0 (baseline) to time t (AUC(0-t)), and AUC from baseline to infinity (AUC(0-infinity)), blood samples were drawn at baseline and 0.17, 0.33, 0.50, 0.75, 1, 1.25, 1.50, 1.75, 2, 2.50, 3, 4, 6, 8, and 12 hours after administration. The formulations were considered bioequivalent if the natural log (ln)-transformed ratios of C(max) and AUC were within the predetermined equivalence range of 80% to 125%, and if P
机译:背景:奥美拉唑是一种质子泵抑制剂,可减少胃酸分泌,用于治疗各种与酸有关的胃肠道疾病。墨西哥有几种奥美拉唑的通用配方;然而,文献检索未能确定有关这些制剂在墨西哥人口中的生物利用度的公开数据。目的:本研究的目的是比较两种在墨西哥市场出售的奥美拉唑20毫克胶囊口服制剂在健康志愿者中的生物利用度:Inhibitron(R)(测试制剂)和LosecA(R) 20 mg(参考配方)。方法:本研究使用单剂量,开放标签,随机序列,2 x 2交叉(2个给药期x 2种治疗)设计来比较2种制剂。符合条件的受试者是健康的成年墨西哥男女志愿者。受试者以1:1的比例随机分配,以接受20 mg剂量的测试制剂,然后是参考制剂,反之亦然,在给药期之间有7天的洗脱期。禁食12小时(过夜)后,受试者接受20毫克剂量的相应制剂。给药后12小时内获得血浆样品。通过非立体特异性高效液相色谱法分析血浆奥美拉唑浓度。为了分析药代动力学特性,包括C(max),从时间0(基线)到时间t(AUC(0-t))的AUC,以及从基线到无穷大(AUC(0-无穷大))的AUC,抽取了血液样本在基线时以及给药后0.17、0.33、0.50、0.75、1、1.25、1.50、1.75、2、2.50、3、4、6、8和12小时。如果C(max)和AUC的自然对数(ln)转换比率在80%至125%的预定当量范围内,并且90%CI的P≤0.05,则认为该制剂具有生物等效性。通过临床评估,监测生命体征,实验室分析结果以及有关不良事件(AE)的受试者访谈来确定耐受性。当患者的结果是死亡,威胁生命,需要住院治疗,导致残疾或需要干预以防止永久性损害或损害时,认为不良事件很严重。结果:招募了34位受试者并完成了研究(25位男性和9位女性;平均[SD]年龄为24.7 [5.5]岁;体重为64.3 [8.9] kg;身高为167 [8] cm)。 17名受试者首先接受了测试配方。没有观察到周期或顺序效应。 ln C(max),ln AUC(0-t)和ln AUC(0-无穷大)对应差异的90%CI为86.70%至109.76%,93.81%至108.22%和102.09%至114.21% ,分别(所有,P <0.05),满足生物等效性的预定标准。八名患者经历了13次AE,似乎与研究用药无关。没有一个AE被认为是严重的。结论:在这项针对健康墨西哥成年志愿者的小型研究中,根据吸收率和吸收程度,单剂量20 mg的测试制剂似乎与参考制剂具有生物等效性。两种制剂通常耐受良好。

著录项

相似文献

  • 外文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号